Environmental Metaplastic Atrophic Gastritis
ICD-10 K29.4 · ICD-11 DA42.1

Treatment of Environmental Metaplastic Atrophic Gastritis When H. pylori Persists Despite Previous Eradication Therapy

Clinical Scenario

This protocol addresses patients with environmental metaplastic atrophic gastritis (EMAG) who remain H. pylori positive after having already undergone eradication therapy. These treatment-experienced patients require a salvage approach — defined as any eradication regimen given for persistent infection after an initial treatment attempt.

Patient Characteristics

The patient has confirmed persistent H. pylori infection despite prior eradication therapy, is considered treatment-experienced, and has no penicillin allergy. Among the available salvage regimens, eligibility is shaped by which prior treatments the patient has already received.

Treatment Approach (Partial Overview)

Salvage eradication in this setting centres on optimized bismuth quadruple therapy (BQT), a multi-drug regimen recommended for treatment-experienced patients who have not previously received it — including those who received prior PPI-clarithromycin triple therapy.

Full regimen details, component agents, dosing schedule, and decision algorithm are available in the structured protocol below.

Clinical Goals

The primary objective is confirmed eradication of H. pylori, verified by an appropriate test of cure — urea breath test, fecal antigen test, or biopsy-based test — performed at least 4 weeks after completing therapy.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.14309/ajg.0000000000002968

  1. The umbrella term "salvage therapy" refers to any treatment provided to patients with persistent H. pylori infection despite initial therapy.
  2. Of the recommended and suggested salvage regimens, only optimized BQT is suitable for patients with a true penicillin allergy.
  3. In treatment-experienced patients with persistent H. pylori infection who have not previously received BQT, optimized BQT is suggested (conditional recommendation; very low quality of evidence).
  4. In treatment-experienced patients with persistent H. pylori infection who have previously received PPI-clarithromycin triple therapy, optimized BQT is suggested (conditional recommendation; low quality of evidence).
  5. In treatment-experienced patients with persistent H. pylori infection who have not previously received optimized BQT, optimized BQT is suggested over quinolone-based therapy (conditional recommendation; low quality of evidence).
  6. All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 weeks after completion of therapy.
View source ↗